v3.26.1
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2026
Segment Reporting  
Schedule of segment significant expense categories

  ​ ​ ​

Six Months Ended June 30, 

2026

2025

Grant income

$

7,497

$

12,192

Less:

 

 

Clinical programs

6,238

15,051

R&D Personnel costs(1)

3,352

4,973

Preclinical programs

682

225

Manufacturing

583

1,150

Other research and development expenses

92

227

General and administrative expenses(2)

4,959

4,920

Equity-based compensation

649

1,207

Other segment items(3)

 

(556)

 

(347)

Segment and consolidated net loss

$

(8,502)

$

(15,214)

(1) R&D Personnel costs exclude equity-based compensation

(2) General and administrative expenses exclude equity-based compensation

(3) Other segment items include, Other income, net, and Interest expense